ANAVEX2-73 Study in Parkinson's Disease Dementia

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Parkinsons Disease With Dementia
Interventions
DRUG

High dose ANAVEX2-73

Active oral capsule

DRUG

Mid dose ANAVEX2-73

Active oral capsule

DRUG

Placebo oral capsule

Placebo oral capsule

Trial Locations (25)

Unknown

KaRa MINDS, Macquarie Park

Hammond Health, Malvern

Hospital Cruces Bilbao, Barakaldo

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Mutua Terrasa, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario de Burgos, Burgos

Hospital Universitario Puerta del Mar, Cadiz

Hospital del Henares, Coslada

Hospital General Universitario de Elche, Elche

Hospital Arquitecto Marcide, Ferrol

Hospital Santa Caterina, Girona

Clinica Ruber Internacional, Madrid

Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -, Madrid

Hospital Clínico San Carlos, Madrid

Hospital de La Princesa, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Infanta Leónor, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Hospital HM Puerta del Sur, Móstoles

Hospital Universitario Central de Asturias (HUCA), Oviedo

Clínica Universidad de Navarra (CUN), Pamplona

Hospital de Santiago de Compostela, Santiago de Compostela

Hospital Universitario Virgen del Rocío, Seville

Sponsors
All Listed Sponsors
collaborator

Anavex Germany GmbH

INDUSTRY

lead

Anavex Life Sciences Corp.

INDUSTRY